
doi: 10.1002/hem3.70094
pmid: 39981189
pmc: PMC11841198
handle: 11562/1162253 , 11577/3547737 , 11585/1007111 , 2318/2103871 , 11586/532881
doi: 10.1002/hem3.70094
pmid: 39981189
pmc: PMC11841198
handle: 11562/1162253 , 11577/3547737 , 11585/1007111 , 2318/2103871 , 11586/532881
Our findings provide a snapshot of the current therapeutic landscape in WM after cBTKi failure. Importantly, although none of the baseline disease characteristics influenced response to cBTK‐S, the sample size is too small to make any powered evaluation. On this basis, there is an urgent need for approval in this setting. Prospective clinical trials with other targeted agents, immunotherapies, and cellular therapies are currently ongoing in cBTKi‐exposed patients to address this therapeutic gap
Letter, 610, Diseases of the blood and blood-forming organs, Salvage treatment, BTKi failure, unmet need, Waldenstrom macroglobulinemia, RC633-647.5, N.D, Waldenström's macroglobulinemia
Letter, 610, Diseases of the blood and blood-forming organs, Salvage treatment, BTKi failure, unmet need, Waldenstrom macroglobulinemia, RC633-647.5, N.D, Waldenström's macroglobulinemia
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
